1. Anthropic opens a verified-access beta for life-sciences teams1
Anthropic has opened applications for its Life Sciences Verification Program, a beta giving vetted organisations more permissive access to Claude for biological research and drug-development work. Applicants undergo checks of research credentials, security and oversight; access remains tied to declared uses. The company says monitoring replaces some request-time blocking and requires 30-day data retention for programme traffic. For research teams, this changes the practical conditions for using frontier models, including data handling. It is an access programme rather than evidence of scientific reliability, and expansion to individual plans is still planned.1
2. Inductive launches Beacon-2 to integrate dose predictions into compound design2
Inductive Bio has launched Beacon-2 for partners using its Compass platform, combining predicted ADMET properties and potency with mechanistic pharmacokinetic models to estimate human dose. The company presents this as a way to prioritise compounds before synthesis and give design agents a broader objective than potency alone. Its technical evaluation compares predictions with dose projections built from measured laboratory properties, rather than observed doses in patients.3 That distinction matters when interpreting the launch’s performance claims. Beacon-2 adds an integrated decision tool to discovery workflows; prospective experimental and clinical usefulness remains a separate question.2
References
Anthropic. Introducing the Life Sciences Verification Program. Anthropic News; 2026; Responsible-organisation announcement; not a peer-reviewed research paper. Accessed 2026-09-21T16:14:19.154Z.
Source evidence and access
Announcement opening; Verification and access types; How monitoring works; Applications and availability
Evidence paraphrase: organisation beta applications open; verification covers research credentials, security and oversight. Standard grants permit more biology work; programme traffic requires30-day data retention to support monitoring. Individual plans are future expansion. Access programme does not validate scientific conclusions.
Original responsible-organisation public page inspected.
Inductive Bio. Inductive Launches Beacon-2, Making Human Dose Computable for Chemists and AI agents Across Biopharma. Inductive Bio; 2026; Responsible-organisation announcement; not a peer-reviewed research paper. Accessed 2026-09-21T16:14:19.154Z.
Source evidence and access
Launch announcement opening and availability paragraph
Evidence paraphrase: September17 launch combines ADMET and potency predictions with mechanistic PK; available to partners through Compass. Launch claims include a predicted-dose design demonstration, not a measured clinical dose.
Original responsible-organisation public page inspected.
Inductive Bio. Beacon-2: Completing the reward function for chemical optimization in drug discovery. Inductive Bio; 2026; Responsible-organisation announcement; not a peer-reviewed research paper. Accessed 2026-09-21T16:14:19.154Z.
Source evidence and access
How Beacon-2 makes dose computable; Applying Beacon-2; concluding experimental-validation caveat
Evidence paraphrase: public325-compound and20-partner-program comparisons compare computational dose to dose projected from measured ADME, both assuming10nM potency. Technical post says projected doses require wet-lab validation.
Original responsible-organisation public page inspected.
Publication record
Published 2026-09-21.
Sources, selection and claims were checked in an independent AI editorial review, followed by the AI editor's approval. This is not academic peer review.
- 2026-09-21 · Version 0f90a9d2 · Viewing this version